Literature DB >> 19925968

Tuberculosis-associated immune reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral therapy.

Graeme Meintjes1, Helena Rabie, Robert J Wilkinson, Mark F Cotton.   

Abstract

The tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is a frequent early complication of antiretroviral therapy (ART), used to treat HIV-1 infection, especially in countries where TB is prevalent. TB-IRIS is characterized by an exaggerated inflammatory response toward the antigens of Mycobacterium tuberculosis that results in clinical deterioration in patients experiencing immune recovery during early ART. Two forms of TB-IRIS are recognized: paradoxical; and unmasking. Paradoxical TB-IRIS manifests with new or recurrent TB symptoms or signs in patients being treated for TB during early ART, and unmasking TB-IRIS is characterized by an exaggerated, unusually inflammatory initial presentation of TB during early ART. In this review the incidence, clinical features, risk factors, treatment, and prevention of TB-IRIS in adult and pediatric patients are discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19925968     DOI: 10.1016/j.ccm.2009.08.013

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  40 in total

Review 1.  Immunostimulation in the era of the metagenome.

Authors:  Amy D Proal; Paul J Albert; Greg P Blaney; Inge A Lindseth; Chris Benediktsson; Trevor G Marshall
Journal:  Cell Mol Immunol       Date:  2011-01-31       Impact factor: 11.530

2.  HIV-1 and the immune response to TB.

Authors:  Naomi F Walker; Graeme Meintjes; Robert J Wilkinson
Journal:  Future Virol       Date:  2013-01       Impact factor: 1.831

Review 3.  HIV and tuberculosis: a deadly human syndemic.

Authors:  Candice K Kwan; Joel D Ernst
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

4.  Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome in children.

Authors:  Annelies Van Rie; Shobna Sawry; Ruth Link-Gelles; Shabir Madhi; Lee Fairlie; Charl Verwey; Nasreen Mahomed; David Murdoch; Harry Moultrie
Journal:  Pediatr Pulmonol       Date:  2015-06-14

Review 5.  Biomarkers in immune reconstitution inflammatory syndrome: signals from pathogenesis.

Authors:  Irini Sereti; Alison J Rodger; Martyn A French
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

6.  TB-IRIS, T-cell activation, and remodeling of the T-cell compartment in highly immunosuppressed HIV-infected patients with TB.

Authors:  Viraga Haridas; Polidy Pean; Luke D Jasenosky; Yoann Madec; Didier Laureillard; Thim Sok; Sun Sath; Laurence Borand; Olivier Marcy; Sarin Chan; Erdyni Tsitsikov; Jean-François Delfraissy; François-Xavier Blanc; Anne E Goldfeld
Journal:  AIDS       Date:  2015-01-28       Impact factor: 4.177

Review 7.  A systematic review of published literature describing factors associated with tuberculosis recurrence in people living with HIV in Africa.

Authors:  Yoshan Moodley; Kumeren Govender
Journal:  Afr Health Sci       Date:  2015-12       Impact factor: 0.927

8.  The risk and timing of tuberculosis diagnosed in smear-negative TB suspects: a 12 month cohort study in Harare, Zimbabwe.

Authors:  Munyaradzi Dimairo; Peter MacPherson; Tsitsi Bandason; Abbas Zezai; Shungu S Munyati; Anthony E Butterworth; Stanley Mungofa; Simba Rusikaniko; Katherine Fielding; Peter R Mason; Elizabeth L Corbett
Journal:  PLoS One       Date:  2010-07-28       Impact factor: 3.240

Review 9.  Tuberculosis in children.

Authors:  Ben J Marais; H Simon Schaaf
Journal:  Cold Spring Harb Perspect Med       Date:  2014-07-18       Impact factor: 6.915

Review 10.  Tuberculosis Immune Reconstitution Inflammatory Syndrome in children initiating Antiretroviral Therapy for HIV infection: A systematic literature review.

Authors:  Ruth Link-Gelles; Harry Moultrie; Shobna Sawry; David Murdoch; Annelies Van Rie
Journal:  Pediatr Infect Dis J       Date:  2014-05       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.